PRNewsWire
14 Jul 2026, 17:34 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
The law firm Monteverde & Associates PC is investigating NextCure, Inc. (NASDAQ: NXTC) regarding its merger with Avere Therapeutics, Inc. — Legal investigations into mergers can create uncertainty and perceived risk regarding the fairness of the deal terms, potentially depressing the stock price.
-0.30NextCure shareholders are expected to own approximately 1.21% of the combined company following the closing of the proposed transaction. — This is a factual detail of the merger agreement and does not independently signal a change in market direction.
+0.00Which stocks this story touches
The company is the subject of a class action investigation regarding the fairness of its merger deal.
Continue reading
6 related stories
Top 2 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
28m ago
